Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Gujarat Themis Biosyn Ltd (GUJTHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506879 NSE: GUJTHEM Pharmaceuticals & Drugs | Small Cap | Guj. Themis Biosyn Share Price
₹413.10 1.35 (0.33%)
As on 23-Sep'26 11:43
Gujarat Themis Biosyn Ltd (GUJTHEM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506879 NSE: GUJTHEM Pharmaceuticals & Drugs | Small Cap | Guj. Themis Biosyn Share Price
₹413.10 1.35 (0.33%)
As on 23-Sep'26 11:43
Key Metrics
Valuation Multiples
Market Cap
₹5,359 Cr.
Current Price
₹413.1
52-Week Low / High
₹226 / 479
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
9.96%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
70.86%
Pledged shares (%) of Promoter's holding (%)
5.44%
Reserves
-
Equity
₹13 Cr.
Face Value
₹1
All Time Low / High
₹0.20 / 479.45
Check Before You Invest
Quality
Not GoodValuation
FairCheck Valuation charts
Price Trend
Strong
Is Gujarat Themis Biosyn Ltd a good quality company?
Gujarat Themis Biosyn Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Gujarat Themis Biosyn Ltd performance compare with that of its Peers?
Revenue growth of Gujarat Themis Biosyn Ltd vs industry peers?
Gujarat Themis Biosyn Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Gujarat Themis Biosyn Ltd?
Promoters hold 70.86% of the Gujarat Themis Biosyn Ltd, with 5.44% of their stake pledged, indicating low pledge risk.
Stock return of Gujarat Themis Biosyn Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 51.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gujarat Themis Biosyn Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 54.7% | 42.2% | 44.9% | 86% | 67.9% | 67.9% | 61.5% | 45.4% | 27.5% | 18.2% | - |
| Value Creation Index ⓘ | 2.9 | 2.0 | 2.2 | 5.1 | 3.9 | 3.9 | 3.4 | 2.2 | 1.0 | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 35.7 | 38.8 | 41.1 | 85.1 | 90.6 | 115 | 148 | 170 | 151 | 166 | 174 |
| Sales YoY Gr. | - | 8.7% | 5.8% | 107.4% | 6.4% | 26.8% | 29.2% | 14.4% | -11.2% | 10% | - |
| Adj EPS ⓘ | 0.4 | 0.4 | 0.6 | 2.2 | 2.8 | 4 | 5.3 | 5.4 | 4.5 | 4.3 | 3.7 |
| YoY Gr. | - | -10% | 61.1% | 274.1% | 27.7% | 44.4% | 33% | 2.1% | -17.7% | -4.5% | - |
| BVPS (₹) ⓘ | 0.8 | 1.1 | 1.7 | 3.9 | 6.4 | 9.5 | 13.7 | 18.5 | 22.8 | 26.4 | 80.6 |
| Adj Net Profit ⓘ | 4.4 | 3.9 | 6.4 | 23.7 | 30.2 | 43.6 | 58 | 59.2 | 48.7 | 46.6 | 49 |
| Cash Flow from Ops. ⓘ | 2.8 | 5.6 | 0.7 | 0.6 | 10.5 | 40.3 | 39.5 | 64.2 | 91 | 48.8 | - |
| Debt/CF from Ops. ⓘ | 1.4 | 0.1 | 8.8 | 12.9 | 0.3 | 0 | 0 | 0 | 0.3 | 3.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 18.6% | 12.9% | 3.8% | 10% | ||||
| Adj EPS ⓘ | 30.1% | 9% | -7.1% | -4.5% | ||||
| BVPSⓘ | 48.5% | 32.7% | 24.5% | 15.9% | ||||
| Share Price | 51.6% | 38.1% | 52.6% | 1% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 72.5 | 38.1 | 41.6 | 78 | 53.8 | 50.4 | 45.9 | 33.8 | 21.7 | 17.4 | 7 |
| Op. Profit Mgn % ⓘ | 17 | 16.1 | 17.9 | 37.4 | 44.5 | 50.5 | 49.6 | 46.4 | 45.7 | 46.1 | 47.4 |
| Net Profit Mgn % ⓘ | 12.2 | 10 | 15.5 | 27.8 | 33.3 | 38 | 39.1 | 34.9 | 32.3 | 28.1 | 28 |
| Debt to Equity ⓘ | 0.5 | 0.1 | 0.3 | 0.2 | 0 | 0 | 0 | 0 | 0.1 | 0.6 | - |
| Working Cap Days ⓘ | 78 | 73 | 92 | 144 | 204 | 226 | 267 | 245 | 222 | 196 | 74 |
| Cash Conv. Cycle ⓘ | -26 | -22 | -19 | 27 | 54 | 62 | 47 | 24 | 26 | 28 | 14 |
Valuation of Guj. Themis Biosyn - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 3.30 | 3.30 | 3.30 | 3.30 | 3.30 | 0.00 | 3.30 | 4.49 | 5.44 | 5.44 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Gujarat Themis Biosyn Ltd FAQs
The current trading price of Guj. Themis Biosyn on 23-Sep-2026 11:43 is ₹413.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Guj. Themis Biosyn stood at ₹5,359 Cr
The latest P/E ratio of Guj. Themis Biosyn as of 22-Sep-2026 is 110.1.
The latest P/B ratio of Guj. Themis Biosyn as of 22-Sep-2026 is 5.11.
The 52-week high of Guj. Themis Biosyn is ₹479.4 and the 52-week low is ₹225.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Guj. Themis Biosyn is ₹174 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gujarat Themis Biosyn Ltd is a below average quality company.
The key valuation ratios of Gujarat Themis Biosyn Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Gujarat Themis Biosyn Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.
The company has world-wide exports to satisfied customers, having customised facility for all products.
The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.
Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.
Business area of the company
- Pharmaceuticals & Drugs
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
